Cardio Diagnostics Holdings, Inc. is an artificial intelligence-powered precision cardiovascular medicine company. The Company develops and commercializes a series of products for various types of cardiovascular disease and associated co-morbidities, including coronary heart disease (CHD), stroke, heart failure and diabetes, by leveraging its artificial intelligence (AI)-driven Integrated Genetic-Epigenetic Engine. Its first product, Epi+Gen CHD, is an epigenetics-based clinical blood test capable of assessing near-term (three-year) risk for CHD, and its second product, PrecisionCHD, is an epigenetics-based clinical blood test for the detection of CHD. CardioInnovate360 is a research use only (RUO) solution to support the discovery, development, and validation of biopharmaceuticals for the assessment and management of cardiovascular diseases. HeartRisk is a cardiovascular risk intelligence platform that combines insights from anonymized and aggregated clinical cardiovascular data.
회사 코드CDIOW
회사 이름Cardio Diagnostics Holdings Inc
상장일Nov 23, 2021
설립일2021
CEODr. Meeshanthini V. (Meesha) Dogan, Ph.D.
직원 수- -
유형Company Warrant
회계 연도 종료- -
주소311 W. Superior Street
도시CHICAGO
증권 거래소NASDAQ Capital Market Consolidated
국가United States of America
우편 번호60645
전화18552269991
웹사이트
회사 코드CDIOW
상장일Nov 23, 2021
설립일2021
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.

데이터 없음